Welcome to our dedicated page for Regenxbio news (Ticker: RGNX), a resource for investors and traders seeking the latest updates and insights on Regenxbio stock.
Regenxbio Inc (RGNX) is a clinical-stage biotechnology leader advancing novel AAV gene therapies through its proprietary NAV® technology platform. This page provides investors and stakeholders with centralized access to the company’s latest press releases, clinical trial updates, and strategic developments.
Track critical updates across Regenxbio’s pipeline, including progress on RGX-202 for Duchenne muscular dystrophy, RGX-121 for Hunter syndrome, and ABBV-RGX-314 for retinal diseases. Stay informed about regulatory milestones, manufacturing advancements, and partnership announcements with entities like AbbVie.
All content is sourced directly from Regenxbio’s official communications, ensuring accuracy and timeliness. Bookmark this page for streamlined access to essential updates on one-time gene therapies targeting rare genetic disorders.
REGENXBIO Inc. (Nasdaq: RGNX) will participate in several upcoming virtual investor conferences in March 2021. The events include:
- Raymond James 42nd Annual Institutional Investors Conference: March 3, 2021, at 10:50 a.m. ET
- Barclays Global Healthcare Conference: March 9, 2021, at 4:10 p.m. ET
- Morgan Stanley Virtual Healthcare Corporate Access Day: March 16, 2021
Live webcasts for the Raymond James and Barclays events will be available on REGENXBIO's website, with archived versions accessible for 30 days post-event.
REGENXBIO Inc. (RGNX) announced a conference call scheduled for March 1, 2021, at 4:30 p.m. ET, to discuss its financial results for the fourth quarter and full year 2020, along with operational highlights. The call can be accessed via phone or through a webcast on the company's website. REGENXBIO is recognized for its innovative gene therapy solutions using its NAV Technology Platform, which includes a range of adeno-associated virus vectors aimed at therapeutic advancements across various medical fields.
On February 16, 2021, REGENXBIO announced positive interim data from the Phase I/IIa trial of RGX-314, a gene therapy for wet age-related macular degeneration (AMD). The treatment demonstrated durability over three years, with significant reductions in anti-VEGF injection burdens. Cohorts 4 and 5 showed stable visual acuity and decreased retinal thickness. Notably, 67% of patients were anti-VEGF injection-free for up to three years. The ATMOSPHERE trial, aimed at validating these findings, is currently enrolling patients. RGX-314's safety profile remains generally well-tolerated.
REGENXBIO Inc. (Nasdaq: RGNX) announced positive interim data from its Phase I/II trial of RGX-121 for treating Mucopolysaccharidosis Type II (MPS II, Hunter Syndrome) in children. Presented at the 17th Annual WORLD Symposium, the results from eight patients show a favorable safety profile and improvements in biomarker levels, indicating enhanced enzyme activity. RGX-121 aims to deliver the I2S enzyme gene via an AAV9 vector, with plans to commence patient enrollment for Cohort 3 at a higher dose in Q1 2021.
REGENXBIO Inc. (Nasdaq: RGNX) announced its participation in the Angiogenesis, Exudation, and Degeneration 2021 conference on February 12-13, 2021. Two oral presentations will showcase advancements in gene therapy for eye diseases:
- Subretinal Gene Therapy for Exudative AMD by Allen C. Ho, M.D. on February 13 at 9:15 a.m. ET
- Suprachoroidal Gene Therapy for Exudative AMD and Diabetic Retinopathy by Peter A. Campochiaro, M.D. on February 13 at 9:45 a.m. ET
These presentations highlight the company's innovative approaches using its NAV® Technology Platform.
REGENXBIO Inc. (Nasdaq: RGNX) has announced three oral and nine poster presentations for the 17th Annual WORLD Symposium™ from February 8-12, 2021. Key presentations include interim results from the Phase I/II trial of RGX-121 targeting mucopolysaccharidosis type II (MPS II). Notable presentations cover comparative effectiveness of gene therapies and clinical updates on RGX-121. REGENXBIO is focused on advancing its NAV Technology Platform for gene therapy applications, with exclusive rights to over 100 AAV vectors.
REGENXBIO Inc. (Nasdaq: RGNX) has successfully closed its public offering of 4,260,000 common stock shares at $47.00 each, yielding approximately $230.3 million in gross proceeds after the underwriters' full option exercise for an additional 639,000 shares. This offering was managed by BofA Securities, Morgan Stanley, and Barclays. The shares were offered under a shelf registration statement effective since August 8, 2018. The funds raised will support REGENXBIO's ongoing gene therapy developments utilizing its proprietary NAV Technology Platform.
REGENXBIO Inc. (Nasdaq: RGNX) announced its presentation at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 11:40 a.m. ET. This virtual conference will showcase the company's advancements in gene therapy. A webcast will be available on REGENXBIO's website, with an archived replay accessible for 30 days. The company utilizes its proprietary NAV Technology Platform to develop innovative gene delivery systems across multiple therapeutic areas.
REGENXBIO Inc. (Nasdaq: RGNX) has priced a public offering of 4,260,000 shares of common stock at $47.00 per share. The offering is expected to generate approximately $200.2 million in gross proceeds before deductions. Closing is anticipated on January 12, 2021, subject to customary conditions. An additional 639,000 shares may be purchased by underwriters within 30 days. This offering is conducted under a shelf registration statement with the SEC, aiming to support REGENXBIO's ongoing gene therapy initiatives.
REGENXBIO Inc. (Nasdaq:RGNX) announced a proposed underwritten public offering of $175 million in common stock, subject to market conditions. The offering may include an additional 15% of shares at the underwriters' option. BofA Securities, Morgan Stanley, and Barclays are managing the offering. This action follows a shelf registration statement filed with the SEC in August 2018. The funds raised will likely support REGENXBIO's gene therapy initiatives based on its proprietary NAV® Technology Platform, which includes over 100 novel AAV vectors.
